SynthesisBMC cardiovascular disorders2025
Clinical outcomes of transcatheter edge-to-edge repair in patients with acute mitral regurgitation complicated by cardiogenic shock: a systematic review and meta-analysis.
Synthesis in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Edge-to-Edge Mitral Valve Repair for Severe Regurgitation in Cardiogenic Shock: A Comprehensive Review.Journal of cardiovascular development and disease · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute mitral regurgitation (AMR) complicated by cardiogenic shock (CS) is a critical cardiovascular emergency associated with high morbidity and mortality. Surgical intervention is often not feasible due to the unstable clinical status of these patients. Transcatheter edge-to-edge repair (TEER) has emerged as a minimally invasive alternative, yet its safety and efficacy in this specific population remain uncertain. This study aimed to systematically evaluate and synthesize the evidence on the clinical outcomes of TEER in patients with AMR complicated by CS.
methodsDatabases including PubMed, Embase, and Web of Science were searched through March 4, 2025. Eligible studies included adult patients with AMR and CS undergoing TEER and reporting clinical outcomes. Data were synthesized using a random-effects model.
resultsThe pooled in-hospital mortality rate following TEER was 17.8% (95% CI: 11.2-25.2%). One-month mortality was 7.9% (95% CI: 1.1-16.8%), six-month mortality was 21.0% (95% CI: 11.2-32.7%), and one-year mortality was 36.5% (95% CI: 34.9-38.2%). Among patients with degenerative MR, the one-year mortality was 7.9% (95% CI: 0.8-19.0%), while for functional MR it was 9.4% (95% CI: 1.3-21.5%). Postprocedural MR reduction to ≤ grade 2 was achieved in 86.2% of patients (95% CI: 70.7-97.3%). The intra-aortic balloon pump (IABP) application rate was 57.9% (95% CI: 24.2%-88.5%). Compared to usual care, TEER significantly reduced in-hospital mortality (OR = 0.64; 95% CI: 0.51-0.81; P < 0.01). However, no significant reduction was found in rehospitalization risk (OR = 0.65; 95% CI: 0.14-3.03; P = 0.59).
conclusionTEER appears to be a promising therapeutic option for patients with AMR complicated by CS. Compared to usual care, it is associated with significantly lower in-hospital mortality. However, high heterogeneity and low certainty of evidence highlight the need for further high-quality prospective studies to validate long-term outcomes and optimize patient selection. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.